Experience of Temozolomide Mono- and Combination Therapy in Advanced Neuroendocrine Tumors (NETs) in Russia Abstract #910

Introduction: Temozolomide (T) demonstrated promising activity in NETs in numerous phase 2 studies worldwide. But there is not enough data about its efficacy in the Russian population.
Aim(s): To evaluate efficacy and tolerability of T mono- and combination therapy in advanced NETs.
Materials and methods: Twenty-seven patients (pts) with advanced NETs (10 pancreatic NETs, seven GI NETs, three bronchial carcinoids, two kidney NETs, one mediastinal and three NETs without primary) were treated with T in monotherapy (five pts) or combination regimens, which included T+nitrosourea derivatives (10 pts), T+irinotecan (seven pts), T+capecitabine (four pts) and combination with cisplatin (one pt). Primary tumor site was resected in 14 patients. Most of the patients received long-acting octreotide. Ten pts were chemotherapy-naive. The median time from initial diagnosis till treatment initiation was seven months. The mean age was 57 years (26-78), 12 females, 15 males. Tumor differentiation was as follows: Grade 1 in one patient (3.7%), Grade 2 in 24 patients (89%) and Grade 3 in two patients (7.3%).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Alexander Kuzminov

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova
#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Kuznetsova
#474 Difficulties in Diagnosis and Management of Neuroendocrine Tumors of the Head and Neck: A Case Report
Introduction: Primary neuroendocrine carcinomas (NEC) are uncommon head and neck malignancies. They present with a varied histopathologic spectrum in sinonasal and other subsites.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Alla Markovich
#659 Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)
Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Alexander Kuzminov
#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova